Life Sciences & Pharma COVID-19 European Disease Progression Monitor: Edition 4 April 20, 2020 Italy, Spain and France are now several weeks past peak virus intensity, taking approximately two weeks to reach 50% of peak levels
Life Sciences & Pharma Special Report Weighing the Trade-offs of a Direct Presence in Japan’s Rare and Orphan Drug Market February 20, 2020 In recent years, there has been a marked uptick in the number of rare and orphan companies establishing local operations in Japan to steward their…
Life Sciences & Pharma Executive Insights Five Essential Factors for a Successful Biopharma Product Launch November 25, 2019 Rapid changes in the biopharma industry are making it increasingly difficult to launch new products successfully.
Strategy COVID-19 Global Situation Report Insights: Edition 2 June 9, 2020 The L.E.K. Global Situation Report is a uniquely rich, current, and customisable collection of indicators that provide a powerful recovery planning aide.
Life Sciences & Pharma COVID-19 COVID-19 Therapeutic Research and Development Landscape June 3, 2020 The following materials provide a snapshot of the unprecedented scope and speed of biopharma’s therapeutics research and development (R&D) response to…
Life Sciences & Pharma COVID-19 European Disease Progression Monitor: Edition 1 March 27, 2020 L.E.K. has identified 5 phases of disease progression, defined by the death rate, with the possibility of repeated cycles if countries suffer viral…
